Overview
- The offering comprises 25,000,000 shares, with a 30-day option for underwriters to buy up to 3,750,000 additional shares.
- Shares are expected to start trading on the Nasdaq Global Select Market on February 27 under the ticker GENB, with closing targeted for March 2 subject to customary conditions.
- Goldman Sachs and Morgan Stanley serve as joint lead book-running managers, joined by Piper Sandler, Guggenheim Securities, and Cantor as book-runners.
- All shares are being sold by the company following SEC effectiveness of the registration on February 26.
- Generate plans to allocate roughly $300 million to Phase III trials of GB-0895 for severe asthma and about $100 million to COPD development, according to its filing.